These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20605760)

  • 1. Recent EORTC and MRC UK studies: implications for imaging ovarian cancer.
    Spencer JA; Perren TJ
    Cancer Imaging; 2010 Jul; 10(1):135-6. PubMed ID: 20605760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
    Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
    J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer.
    Mironov S; Akin O; Pandit-Taskar N; Hann LE
    Radiol Clin North Am; 2007 Jan; 45(1):149-66. PubMed ID: 17157627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
    Grønlund B
    Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue polypeptide-specific antigen (TPS) as tumour marker in epithelial ovarian cancer.
    Blokkebak-Poulsen J; Mogensen O; Mogensen B
    Acta Oncol; 1997; 36(4):433-5. PubMed ID: 9247106
    [No Abstract]   [Full Text] [Related]  

  • 6. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F-FDG PET/CT in patients, treated for ovarian cancer, with elevated CA 125 levels but no evidence of recurrence on conventional imaging].
    Bochev P; Bocheva Y; Klisarova A; Ivanov S; Dancheva J; Chaushev B
    Akush Ginekol (Sofiia); 2012; 51(1):18-27. PubMed ID: 22639775
    [No Abstract]   [Full Text] [Related]  

  • 8. [Role of second-look surgery in treatment of ovarian neoplasms].
    Markowska J; Szewierski Z; Roszak A; Niecewicz R
    Ginekol Pol; 1996 Apr; 67(4):200-4. PubMed ID: 8846933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neoadjuvant chemotherapy and ovarian cancer].
    Ray-Coquard I; Saba C; Bachelot T; Méeus P; Mignotte H; Blondet R; Treilleux I; Peix M; Guastalla JP
    Bull Cancer; 2006 Jul; 93(7):669-76. PubMed ID: 16873075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advanced ovarian cancer: upfront or interval debulcking surgery?].
    Narducci F; Bats AS; Loic B; Bensaïd C; Lécuru F
    Bull Cancer; 2009 Dec; 96(12):1183-8. PubMed ID: 19948449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
    Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
    World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of ovarian cancer: promise and reality.
    Bast RC; Urban N; Shridhar V; Smith D; Zhang Z; Skates S; Lu K; Liu J; Fishman D; Mills G
    Cancer Treat Res; 2002; 107():61-97. PubMed ID: 11775462
    [No Abstract]   [Full Text] [Related]  

  • 14. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
    Kessous R; Wissing MD; Piedimonte S; Abitbol J; Kogan L; Laskov I; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    Acta Obstet Gynecol Scand; 2020 Jul; 99(7):933-940. PubMed ID: 31954071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer.
    Tsuda H; Hashiguchi Y; Nakata S; Deguchi M; Negoro S; Ishiko O; Yamamoto K
    Int J Gynecol Cancer; 2002; 12(5):435-7. PubMed ID: 12366658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery for relapsed ovarian cancer: when should it be offered?
    Harter P; Heitz F; du Bois A
    Curr Oncol Rep; 2012 Dec; 14(6):539-43. PubMed ID: 22918696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.
    Markowska J; Wilkoszarska J; Emerich J; Debniak J; Popiela A; Pańszczak M; Kornafel J; Rossochacka B; Fisher Z; Goluda M; Małecki P
    Eur J Gynaecol Oncol; 2000; 21(2):164-7. PubMed ID: 10843477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum markers as prognostic factors in epithelial ovarian cancer: an overview.
    Maggino T; Gadducci A
    Eur J Gynaecol Oncol; 2000; 21(1):64-9. PubMed ID: 10726623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.